Tags

Type your tag names separated by a space and hit enter

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
J Bone Miner Res. 2009 Jul; 24(7):1308-13.JB

Abstract

Annual infusions of zoledronic acid (5 mg) significantly reduced the risk of vertebral, hip, and nonvertebral fractures in a study of postmenopausal women with osteoporosis and significantly reduced clinical fractures and all-cause mortality in another study of women and men who had recently undergone surgical repair of hip fracture. In this analysis, we examined whether timing of the first infusion of zoledronic acid study drug after hip fracture repair influenced the antifracture efficacy and mortality benefit observed in the study. A total of 2127 patients (1065 on active treatment and 1062 on placebo; mean age, 75 yr; 76% women and 24% men) were administered zoledronic acid or placebo within 90 days after surgical repair of an osteoporotic hip fracture and annually thereafter, with a median follow-up time of 1.9 yr. Median time to first dose after the incident hip fracture surgery was approximately 6 wk. Posthoc analyses were performed by dividing the study population into 2-wk intervals (calculated from time of first infusion in relation to surgical repair) to examine effects on BMD, fracture, and mortality. Analysis by 2-wk intervals showed a significant total hip BMD response and a consistent reduction of overall clinical fractures and mortality in patients receiving the first dose 2-wk or later after surgical repair. Clinical fracture subgroups (vertebral, nonvertebral, and hip) were also reduced, albeit with more variation and 95% CIs crossing 1 at most time points. We concluded that administration of zoledronic acid to patients suffering a low-trauma hip fracture 2 wk or later after surgical repair increases hip BMD, induces significant reductions in the risk of subsequent clinical vertebral, nonvertebral, and hip fractures, and reduces mortality.

Authors+Show Affiliations

Novartis Pharma, Basel, Switzerland. efinkeriksen@live.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19257818

Citation

Eriksen, Erik Fink, et al. "Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, vol. 24, no. 7, 2009, pp. 1308-13.
Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24(7):1308-13.
Eriksen, E. F., Lyles, K. W., Colón-Emeric, C. S., Pieper, C. F., Magaziner, J. S., Adachi, J. D., Hyldstrup, L., Recknor, C., Nordsletten, L., Lavecchia, C., Hu, H., Boonen, S., & Mesenbrink, P. (2009). Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 24(7), 1308-13. https://doi.org/10.1359/jbmr.090209
Eriksen EF, et al. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture. J Bone Miner Res. 2009;24(7):1308-13. PubMed PMID: 19257818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. AU - Eriksen,Erik Fink, AU - Lyles,Kenneth W, AU - Colón-Emeric,Cathleen S, AU - Pieper,Carl F, AU - Magaziner,Jay S, AU - Adachi,Jonathan D, AU - Hyldstrup,Lars, AU - Recknor,Chris, AU - Nordsletten,Lars, AU - Lavecchia,Catherine, AU - Hu,Huilin, AU - Boonen,Steven, AU - Mesenbrink,Peter, PY - 2009/3/5/entrez PY - 2009/3/5/pubmed PY - 2009/9/30/medline SP - 1308 EP - 13 JF - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JO - J Bone Miner Res VL - 24 IS - 7 N2 - Annual infusions of zoledronic acid (5 mg) significantly reduced the risk of vertebral, hip, and nonvertebral fractures in a study of postmenopausal women with osteoporosis and significantly reduced clinical fractures and all-cause mortality in another study of women and men who had recently undergone surgical repair of hip fracture. In this analysis, we examined whether timing of the first infusion of zoledronic acid study drug after hip fracture repair influenced the antifracture efficacy and mortality benefit observed in the study. A total of 2127 patients (1065 on active treatment and 1062 on placebo; mean age, 75 yr; 76% women and 24% men) were administered zoledronic acid or placebo within 90 days after surgical repair of an osteoporotic hip fracture and annually thereafter, with a median follow-up time of 1.9 yr. Median time to first dose after the incident hip fracture surgery was approximately 6 wk. Posthoc analyses were performed by dividing the study population into 2-wk intervals (calculated from time of first infusion in relation to surgical repair) to examine effects on BMD, fracture, and mortality. Analysis by 2-wk intervals showed a significant total hip BMD response and a consistent reduction of overall clinical fractures and mortality in patients receiving the first dose 2-wk or later after surgical repair. Clinical fracture subgroups (vertebral, nonvertebral, and hip) were also reduced, albeit with more variation and 95% CIs crossing 1 at most time points. We concluded that administration of zoledronic acid to patients suffering a low-trauma hip fracture 2 wk or later after surgical repair increases hip BMD, induces significant reductions in the risk of subsequent clinical vertebral, nonvertebral, and hip fractures, and reduces mortality. SN - 1523-4681 UR - https://www.unboundmedicine.com/medline/citation/19257818/Antifracture_efficacy_and_reduction_of_mortality_in_relation_to_timing_of_the_first_dose_of_zoledronic_acid_after_hip_fracture_ L2 - https://doi.org/10.1359/jbmr.090209 DB - PRIME DP - Unbound Medicine ER -